<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00832169</url>
  </required_header>
  <id_info>
    <org_study_id>D5090C00015</org_study_id>
    <secondary_id>EudractCT: 2008-006552-22</secondary_id>
    <nct_id>NCT00832169</nct_id>
  </id_info>
  <brief_title>Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386</brief_title>
  <official_title>An Open, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD1386 to Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to get information about absorption, distribution, metabolism and
      excretion as well as the tolerability and safety of AZD1386 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excretion (rate+extent) of radioactivity in urine+faeces following oral administration of [14C]AZD1386</measure>
    <time_frame>Until &gt;90% of predicted total radioactivity has been recovered</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in plasma + unchanged AZD1386 in plasma Metabolite profile in plasma+excreta</measure>
    <time_frame>Predose, + postdose 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 48h, 72h, 96h, 120h, 144hPredose + postdose 1h, 4h, 8h, 24h for excreta from predose (baseline) + postdose from 0h continously until 144h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AZD1386 metabolites in plasma+excreta if feasable</measure>
    <time_frame>Predose, 1h, 4h, 8h 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety + tolerability of AZD1386</measure>
    <time_frame>Predose, 2h, 6h, 12h, 24h, 48h, 168h</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1386</intervention_name>
    <description>1 dose of oral solution</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index of 18 - 30 and weight of 50 to 100 kilos.

          -  Healthy volunteer must have regular bowel movements (at least once daily)

        Exclusion Criteria:

          -  History of psychiatric or somatic disease/condition, which may interfere with the
             objectives of the study as judged by the investigator.

          -  A family history of short QT syndrome or sudden cardiac death amongst first degree
             relatives.

          -  Any clinically important abnormalities in heart rhythm, conduction or morphology of
             resting ECG that may interfere with the interpretation of QTc interval changes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj Chetty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca R&amp;D, CPU Alderley Park, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Ståhle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D, Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Macclesfield</city>
        <state>Cheshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten, MD, PhD, Medical Science Director, Emerging Analgesia, Neuroscience</name_title>
    <organization>AstraZeneca R&amp;D Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>Pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

